Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2010 1
2014 4
2015 1
2016 6
2017 3
2018 2
2019 3
2020 8
2021 22
2022 21
2023 14
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

83 results

Results by year

Filters applied: . Clear all
Page 1
Computable phenotype for real-world, data-driven retrospective identification of relapse in ANCA-associated vasculitis.
Scott J, White A, Walsh C, Aslett L, Rutherford MA, Ng J, Judge C, Sebastian K, O'Brien S, Kelleher J, Power J, Conlon N, Moran SM, Luqmani RA, Merkel PA, Tesar V, Hruskova Z, Little MA. Scott J, et al. Among authors: conlon n. RMD Open. 2024 Apr 30;10(2):e003962. doi: 10.1136/rmdopen-2023-003962. RMD Open. 2024. PMID: 38688690 Free article.
Author Correction: Blood-brain barrier disruption and sustained systemic inflammation in individuals with long COVID-associated cognitive impairment.
Greene C, Connolly R, Brennan D, Laffan A, O'Keeffe E, Zaporojan L, O'Callaghan J, Thomson B, Connolly E, Argue R, Meaney JFM, Martin-Loeches I, Long A, Cheallaigh CN, Conlon N, Doherty CP, Campbell M. Greene C, et al. Among authors: conlon n. Nat Neurosci. 2024 Apr 16. doi: 10.1038/s41593-024-01644-0. Online ahead of print. Nat Neurosci. 2024. PMID: 38627595 No abstract available.
Disease-Modifying Treatments for Multiple Sclerosis Affect Measures of Cellular Immune Responses to EBNA-1 Peptides.
Dungan L, Dunne J, Savio M, Kalaszi M, McElheron M, Lynagh Y, O'Driscoll K, Roche C, Qureshi A, Crowley B, Conlon N, Kearney H. Dungan L, et al. Among authors: conlon n. Neurol Neuroimmunol Neuroinflamm. 2024 May;11(3):e200217. doi: 10.1212/NXI.0000000000200217. Epub 2024 Mar 28. Neurol Neuroimmunol Neuroinflamm. 2024. PMID: 38547427 Free article.
Blood-brain barrier disruption and sustained systemic inflammation in individuals with long COVID-associated cognitive impairment.
Greene C, Connolly R, Brennan D, Laffan A, O'Keeffe E, Zaporojan L, O'Callaghan J, Thomson B, Connolly E, Argue R, Meaney JFM, Martin-Loeches I, Long A, Cheallaigh CN, Conlon N, Doherty CP, Campbell M. Greene C, et al. Among authors: conlon n. Nat Neurosci. 2024 Mar;27(3):421-432. doi: 10.1038/s41593-024-01576-9. Epub 2024 Feb 22. Nat Neurosci. 2024. PMID: 38388736 Free PMC article.
Point of care detection of SARS-CoV-2 antibodies and neutralisation capacity-lateral flow immunoassay evaluation compared to commercial assay to inform potential role in therapeutic and surveillance practices.
McGrath J, O'Doherty L, Conlon N, Dunne J, Brady G, Ibrahim A, McCormack W, Walsh C, Domegan L, Walsh S, Kenny C, Allen N, Fleming C, Bergin C. McGrath J, et al. Among authors: conlon n. Front Public Health. 2023 Sep 28;11:1245464. doi: 10.3389/fpubh.2023.1245464. eCollection 2023. Front Public Health. 2023. PMID: 37841735 Free PMC article.
83 results